Advantages of replacing the total PSA assay with the assay for PSA-α1- antichymotrypsin complex for the screening and management of prostate cancer

Journal of Clinical Laboratory Analysis

Volumn 12, Issue 1, 1998, Pages 32-40

  Wu, James T ^a   Liu, Grace H ^a  

^a ARUP LABORATORIES   (United States)

Author keywords

Benign prostate hyperplasia; Free PSA; Percent free PSA

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; ASSAY; CANCER SCREENING; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT MONITORING; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY;

EID: 0031952077     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2825(1998)12:1<32::AID-JCLA6>3.0.CO;2-L     Document Type: Article

References (24)

1. Wu JT. Assay for prostate specific antigen (PSA): current problems and possible solutions: J Clin Lab Anal 8:51-62, 1994.
2. Wu JT: Serum prostate specific antigen assay - An update. Western J Med (Epitomes-Pathology) 162:447-448, 1995.
3. Oesterlmg JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
4. Christensson A, Laurell CB, Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194:755-763, 1990.
5. Vashi AR, Oesterling JE. Percent free prostate-specific antigen: Entering a new era in the detection of prostate cancer. Mayo Found Med Educat Res 72:337-344, 1997.
6. Lilja H, Cockett ATK, Abrahamsson P-A: Prostate specific antigen predominantly forms a complex with alphal-antichymotrypsin in blood. Cancer Supplement 70:230-234, 1992.
7. Wu JT, Zhang P, Wang T, Wilson L, Astill M: Evaluation of free PSA isoforms. PSA complex formation and specificity of anti-PSA antibodies by HPLC and PAGE-immunoblotting techniques. J Clin Lab Anal 1995;9:1-14.
8. Babaian RJ, Pritsche HA, Evans RB: Prostate-specific antigen and the prostate gland volume, correlation and clinical application. J Clin Lab Anal 4:135, 1990.
9. Oesterling JE, Jacobsen SJ, Chute CG, et al.: Serum prostate-specific antigen in a community-based population of healthy men. JAMA 270:860-864, 1993.
10. Hammerer PG, McNeal JE, Stamey TA. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol 153:111-115, 1995.
11. Van Cangh PJ, De Nayer P, Sauvage P, et al.: Free to toal prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate 7:30-34, 1996.
12. Cataiona WJ, Smith DS, Ornstein DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: Enhancement of specificity with free PSA measurements. JAMA 277:1452-1455, 1997.
13. Cataiona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274:1214-1220, 1995.
14. Wu JT, Wilson L, Zhang P, Meikle WA, Stephenson RA: Correlation of serum concentrations of PSA-ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer. J Clin Lab Anal 9:15-24, 1995.
15. Lilja H, Cockett ATK, Abrahamsson P-A: Prostate specific antigen predominantly forms a complex with alphal-antichymotrypsin in blood. Cancer Supplement 70:230-234, 1992.
16. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Can Res 51:222-226, 1991.
17. 1-antichymotrypsin as an indicator of prostate tancer. J Urol 150:100-105, 1993.
18. 1-Anlichymotrypsin. Clin Chem 37:1618-1625, 1991.
19. 1-antichymotrypsin complex. Clin Chem 41:1480-1488, 1995.
20. Wu JT, Zhang P, Liu GH, Wilson L: Development of an immunoassay specific for the PSA-ACT complex without the problem of high background (submitted).
21. van Duijnhoven HLP, Pequeriaux NCV, van Zon John PHM, Blankenstein MA: Large discrepancy between prostate-specific antigen results from different assays during longitudinal follow-up of a prostate cancer patient. Clin Chem 42:637-641, 1996.
22. Wu JT, Stephenson RA: Microplate assays for free PSA, PSA-ACT and total PSA: assay characteristics, selection of calibrators and in vitro stability studies. Proceeding of the 1st International Consultation on Prostate Cancer, 1997, p 159-168.
23. Benson MC, Whang IS, Pantuck A, et al.: Prostate-specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147:815-816, 1992.
24. Zlotta AR, Djavan B, Marberger M, Schulman CC: Prostate specific antigen density of the transition zone: A new effective parameter for prostate cancer prediction. J Urol 157:1315-1321, 1997.